Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Stanford University NCCN - National Comprehensive Cancer Network |
---|---|
Information provided by: | Stanford University |
ClinicalTrials.gov Identifier: | NCT00537056 |
To learn whether FDG PET/CT and DCE MRI are better predictors of response to therapy than the current standard of care (CT or MRI).
Condition | Intervention |
---|---|
Kidney Neoplasms Carcinoma, Renal Cell |
Drug: Sunitinib Procedure: FDG PET Procedure: PET/CT |
Study Type: | Interventional |
Study Design: | Diagnostic, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI |
Estimated Enrollment: | 20 |
Study Start Date: | October 2007 |
Estimated Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:- Measurable disease by RECIST criteria
Exclusion Criteria:- Patients who cannot complete a PET/CT scan.
Contact: Peralta Dana | (650) 725-1730 | pdawn07@stanford.edu |
United States, California | |
Stanford University School of Medicine | Recruiting |
Stanford, California, United States, 94305 | |
Contact: Peralta Dana 650-725-1730 pdawn07@stanford.edu | |
Contact: Cancer Clinical Trials Office (650) 498-7061 | |
Principal Investigator: Dr Andrew Quon | |
Sub-Investigator: Robert J Herfkens | |
Sub-Investigator: Dr Terry Desser |
Principal Investigator: | Dr Andrew Quon | Stanford University |
Responsible Party: | Stanford University School of Medicine ( Dr Andrew Quon, Principal Investigator ) |
Study ID Numbers: | RENAL0013, 97807, NCT00537056, RENAL0013 |
Study First Received: | September 26, 2007 |
Last Updated: | July 27, 2009 |
ClinicalTrials.gov Identifier: | NCT00537056 History of Changes |
Health Authority: | United States: Institutional Review Board |
Urinary Tract Neoplasm Kidney Cancer Urogenital Neoplasms Urologic Neoplasms Angiogenesis Inhibitors Carcinoma Renal Cancer |
Urologic Diseases Kidney Neoplasms Sunitinib Carcinoma, Renal Cell Kidney Diseases Adenocarcinoma Neoplasms, Glandular and Epithelial |
Neoplasms by Histologic Type Antineoplastic Agents Growth Substances Physiological Effects of Drugs Urogenital Neoplasms Urologic Neoplasms Angiogenesis Inhibitors Pharmacologic Actions Carcinoma Neoplasms Neoplasms by Site |
Urologic Diseases Kidney Neoplasms Sunitinib Therapeutic Uses Carcinoma, Renal Cell Growth Inhibitors Angiogenesis Modulating Agents Kidney Diseases Adenocarcinoma Neoplasms, Glandular and Epithelial |